Alvotech (ALVO) Competitors

$3.46 -0.14 (-3.76%)

As of 03:11 PM Eastern

ALVO vs. AMRX, TVTX, EWTX, ACAD, and TLX

Should you buy Alvotech stock or one of its competitors? MarketBeat compares Alvotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alvotech include Amneal Pharmaceuticals (AMRX), Travere Therapeutics (TVTX), Edgewise Therapeutics (EWTX), ACADIA Pharmaceuticals (ACAD), and Telix Pharmaceuticals (TLX). These companies are all part of the "pharmaceutical products" industry.

How does Alvotech compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

Amneal Pharmaceuticals has a net margin of 4.01% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-272.31%	7.48%
Alvotech	-14.36%	-11.92%	-7.58%

Amneal Pharmaceuticals has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Alvotech has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market.

Amneal Pharmaceuticals has higher revenue and earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.32	$72.06M	$0.38	33.29
Alvotech	$588.90M	1.77	$27.92M	-$0.25	N/A

Amneal Pharmaceuticals currently has a consensus target price of $15.00, indicating a potential upside of 18.57%. Alvotech has a consensus target price of $7.60, indicating a potential upside of 119.97%. Given Alvotech's higher possible upside, analysts plainly believe Alvotech is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Alvotech had 8 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 14 mentions for Alvotech and 6 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.43 beat Alvotech's score of -0.07 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alvotech	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Amneal Pharmaceuticals beats Alvotech on 12 of the 16 factors compared between the two stocks.

How does Alvotech compare to Travere Therapeutics?

Alvotech (NASDAQ:ALVO) and Travere Therapeutics (NASDAQ:TVTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

Travere Therapeutics has a net margin of -4.00% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat Travere Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-14.36%	-11.92%	-7.58%
Travere Therapeutics	-4.00%	-26.16%	-3.71%

Alvotech has a beta of 0.21, suggesting that its share price is 79% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

Alvotech has higher revenue and earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$588.90M	1.77	$27.92M	-$0.25	N/A
Travere Therapeutics	$490.73M	8.08	-$25.55M	-$0.23	N/A

Alvotech presently has a consensus target price of $7.60, suggesting a potential upside of 119.97%. Travere Therapeutics has a consensus target price of $47.83, suggesting a potential upside of 12.11%. Given Alvotech's higher possible upside, analysts plainly believe Alvotech is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

In the previous week, Travere Therapeutics had 40 more articles in the media than Alvotech. MarketBeat recorded 54 mentions for Travere Therapeutics and 14 mentions for Alvotech. Travere Therapeutics' average media sentiment score of 0.35 beat Alvotech's score of -0.07 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alvotech	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Travere Therapeutics	23 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Travere Therapeutics beats Alvotech on 9 of the 14 factors compared between the two stocks.

How does Alvotech compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

Alvotech has higher revenue and earnings than Edgewise Therapeutics. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than Alvotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A
Alvotech	$588.90M	1.77	$27.92M	-$0.25	N/A

Edgewise Therapeutics currently has a consensus target price of $39.67, suggesting a potential upside of 17.01%. Alvotech has a consensus target price of $7.60, suggesting a potential upside of 119.97%. Given Alvotech's higher probable upside, analysts plainly believe Alvotech is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Edgewise Therapeutics has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-32.55%	-31.04%
Alvotech	-14.36%	-11.92%	-7.58%

Edgewise Therapeutics has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.21, meaning that its share price is 79% less volatile than the broader market.

In the previous week, Edgewise Therapeutics had 2 more articles in the media than Alvotech. MarketBeat recorded 16 mentions for Edgewise Therapeutics and 14 mentions for Alvotech. Edgewise Therapeutics' average media sentiment score of 0.71 beat Alvotech's score of -0.07 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alvotech	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Edgewise Therapeutics and Alvotech tied by winning 7 of the 14 factors compared between the two stocks.

How does Alvotech compare to ACADIA Pharmaceuticals?

Alvotech (NASDAQ:ALVO) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to Alvotech's net margin of -14.36%. ACADIA Pharmaceuticals' return on equity of 9.61% beat Alvotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-14.36%	-11.92%	-7.58%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

Alvotech currently has a consensus price target of $7.60, suggesting a potential upside of 119.97%. ACADIA Pharmaceuticals has a consensus price target of $31.00, suggesting a potential upside of 42.37%. Given Alvotech's higher possible upside, equities analysts clearly believe Alvotech is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
ACADIA Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.75

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 26.2% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Alvotech has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.86, indicating that its share price is 14% less volatile than the broader market.

ACADIA Pharmaceuticals has higher revenue and earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$588.90M	1.77	$27.92M	-$0.25	N/A
ACADIA Pharmaceuticals	$1.07B	3.48	$391M	$2.20	9.90

In the previous week, ACADIA Pharmaceuticals had 23 more articles in the media than Alvotech. MarketBeat recorded 37 mentions for ACADIA Pharmaceuticals and 14 mentions for Alvotech. Alvotech's average media sentiment score of -0.07 beat ACADIA Pharmaceuticals' score of -0.19 indicating that Alvotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alvotech	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	7 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

ACADIA Pharmaceuticals beats Alvotech on 15 of the 17 factors compared between the two stocks.

How does Alvotech compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Alvotech (NASDAQ:ALVO) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk, dividends and media sentiment.

Telix Pharmaceuticals has a net margin of 0.00% compared to Alvotech's net margin of -14.36%. Telix Pharmaceuticals' return on equity of 0.00% beat Alvotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Alvotech	-14.36%	-11.92%	-7.58%

Telix Pharmaceuticals presently has a consensus price target of $21.13, suggesting a potential upside of 104.15%. Alvotech has a consensus price target of $7.60, suggesting a potential upside of 119.97%. Given Alvotech's higher probable upside, analysts clearly believe Alvotech is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Telix Pharmaceuticals has a beta of 0.08, meaning that its stock price is 92% less volatile than the broader market. Comparatively, Alvotech has a beta of 0.21, meaning that its stock price is 79% less volatile than the broader market.

Alvotech has lower revenue, but higher earnings than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.37	-$7.12M	N/A	N/A
Alvotech	$588.90M	1.77	$27.92M	-$0.25	N/A

In the previous week, Alvotech had 4 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 14 mentions for Alvotech and 10 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 1.41 beat Alvotech's score of -0.07 indicating that Telix Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	3 Very Positive mention(s)	4 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alvotech	1 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Telix Pharmaceuticals beats Alvotech on 9 of the 13 factors compared between the two stocks.

Get Alvotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALVO vs. The Competition

Export

Metric	Alvotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.04B	$3.41B	$6.27B	$12.13B
Dividend Yield	N/A	2.25%	2.78%	5.23%
P/E Ratio	-13.82	15.30	20.53	25.45
Price / Sales	1.77	302.57	545.62	75.37
Price / Cash	14.96	56.93	27.81	36.29
Price / Book	-3.68	6.81	9.60	6.64
Net Income	$27.92M	$24.11M	$3.55B	$333.40M
7 Day Performance	-1.29%	-1.67%	-0.34%	-0.45%
1 Month Performance	-4.56%	3.64%	6.09%	7.83%
1 Year Performance	-66.29%	70.97%	38.53%	35.63%

Alvotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALVO Alvotech	3.8723 of 5 stars	$3.46 -3.8%	$7.60 +120.0%	-62.9%	$1.04B	$588.90M	N/A	1,460	News Coverage Earnings Report
AMRX Amneal Pharmaceuticals	3.3353 of 5 stars	$13.33 +1.7%	$15.00 +12.5%	+72.2%	$4.19B	$3.02B	35.08	8,500	Earnings Report
TVTX Travere Therapeutics	2.0056 of 5 stars	$44.45 -1.0%	$46.58 +4.8%	+117.3%	$4.11B	$490.73M	N/A	460	Analyst Downgrade
EWTX Edgewise Therapeutics	2.2102 of 5 stars	$38.16 +21.3%	$38.13 -0.1%	+137.0%	$4.10B	N/A	N/A	60	News Coverage Earnings Report Analyst Revision High Trading Volume
ACAD ACADIA Pharmaceuticals	4.3596 of 5 stars	$22.32 +0.6%	$31.21 +39.9%	+25.0%	$3.82B	$1.07B	9.74	510	Earnings Report Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALVO) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alvotech (ALVO) Competitors

ALVO vs. AMRX, TVTX, EWTX, ACAD, and TLX

How does Alvotech compare to Amneal Pharmaceuticals?

Summary

How does Alvotech compare to Travere Therapeutics?

Summary

How does Alvotech compare to Edgewise Therapeutics?

Summary

How does Alvotech compare to ACADIA Pharmaceuticals?

Summary

How does Alvotech compare to Telix Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVO vs. The Competition

Alvotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alvotech (ALVO) Competitors

ALVO vs. AMRX, TVTX, EWTX, ACAD, and TLX

How does Alvotech compare to Amneal Pharmaceuticals?

Is AMRX or ALVO more profitable?

Which has more volatility and risk, AMRX or ALVO?

Which has preferable valuation and earnings, AMRX or ALVO?

Do analysts recommend AMRX or ALVO?

Does the media prefer AMRX or ALVO?

Do institutionals and insiders have more ownership in AMRX or ALVO?

Summary

How does Alvotech compare to Travere Therapeutics?

Is ALVO or TVTX more profitable?

Which has more risk and volatility, ALVO or TVTX?

Which has higher earnings & valuation, ALVO or TVTX?

Do analysts rate ALVO or TVTX?

Does the media refer more to ALVO or TVTX?

Summary

How does Alvotech compare to Edgewise Therapeutics?

Which has stronger valuation and earnings, EWTX or ALVO?

Do analysts prefer EWTX or ALVO?

Is EWTX or ALVO more profitable?

Which has more risk & volatility, EWTX or ALVO?

Does the media favor EWTX or ALVO?

Summary

How does Alvotech compare to ACADIA Pharmaceuticals?

Is ALVO or ACAD more profitable?

Do analysts rate ALVO or ACAD?

Do institutionals & insiders hold more shares of ALVO or ACAD?

Which has more volatility and risk, ALVO or ACAD?

Which has higher valuation & earnings, ALVO or ACAD?

Does the media favor ALVO or ACAD?

Summary

How does Alvotech compare to Telix Pharmaceuticals?

Is TLX or ALVO more profitable?

Do analysts prefer TLX or ALVO?

Which has more risk and volatility, TLX or ALVO?

Which has better earnings and valuation, TLX or ALVO?

Does the media favor TLX or ALVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVO vs. The Competition

Alvotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools